董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John Adams | 男 | Director | 61 | 5.65万美元 | 未持股 | 2023-04-11 |
| John Dyett | 男 | Director | 53 | 9.05万美元 | 未持股 | 2023-04-11 |
| Charles Larsen | 男 | Director,Chairman | 71 | 8.92万美元 | 未持股 | 2023-04-11 |
| Anne Morrissey | 女 | Director | 56 | 6.42万美元 | 未持股 | 2023-04-11 |
| Edward Uzialko | 男 | Director | 72 | 5.07万美元 | 未持股 | 2023-04-11 |
| Kathy Lee Sepsick | 女 | Founder, President, Chief Executive Officer and Director | 55 | 65.90万美元 | 未持股 | 2023-04-11 |
| Wendy Perrow | 女 | Director | 65 | 9.66万美元 | 未持股 | 2023-04-11 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kathy Lee Sepsick | 女 | Founder, President, Chief Executive Officer and Director | 55 | 65.90万美元 | 未持股 | 2023-04-11 |
| Daniel Currie | 男 | Senior Vice President, Operations | 59 | 50.57万美元 | 未持股 | 2023-04-11 |
| Edward Evantash | 男 | Chief Medical Officer | 60 | 未披露 | 未持股 | 2023-04-11 |
| Christine Thomas | 女 | Senior Vice President, Regulatory and Clinical Affairs | 50 | 未披露 | 未持股 | 2023-04-11 |
| Dov Elefant | 男 | Chief Financial Officer | 55 | 60.16万美元 | 未持股 | 2023-04-11 |
董事简历
中英对照 | 中文 | 英文- John Adams
-
John Adams自2015年4月起担任董事会成员。亚当斯先生曾担任亚当斯呼吸疗法公司首席执行官，并于2003年至2008年担任其总裁。Adams Respiratory开发了Mucinex，随后被利洁时以23亿美元收购。Adams先生自2009年以来创立并管理Legacy Capital Partners，LLC，这是一家专注于医疗保健技术和制药开发的投资管理和私募股权公司。亚当斯先生毕业于德克萨斯州谢尔曼市的奥斯汀学院，获得商业学士学位。
John Adams,has served as a member of Femasys Inc. board of directors since April 2015. Mr. Adams has served as Chief Executive Officer of Adams Respiratory Therapeutics Inc. and served as its President from 2003 to 2008. Adams Respiratory developed Mucinex and was subsequently acquired by Reckitt Benckiser for $2.3 billion. Mr. Adams founded and has managed Legacy Capital Partners, LLC, an investment management and private equity firm focused on healthcare technology and pharmaceutical development, since 2009. Mr. Adams is a graduate of Austin College in Sherman, Texas with a BA in Business. - John Adams自2015年4月起担任董事会成员。亚当斯先生曾担任亚当斯呼吸疗法公司首席执行官，并于2003年至2008年担任其总裁。Adams Respiratory开发了Mucinex，随后被利洁时以23亿美元收购。Adams先生自2009年以来创立并管理Legacy Capital Partners，LLC，这是一家专注于医疗保健技术和制药开发的投资管理和私募股权公司。亚当斯先生毕业于德克萨斯州谢尔曼市的奥斯汀学院，获得商业学士学位。
- John Adams,has served as a member of Femasys Inc. board of directors since April 2015. Mr. Adams has served as Chief Executive Officer of Adams Respiratory Therapeutics Inc. and served as its President from 2003 to 2008. Adams Respiratory developed Mucinex and was subsequently acquired by Reckitt Benckiser for $2.3 billion. Mr. Adams founded and has managed Legacy Capital Partners, LLC, an investment management and private equity firm focused on healthcare technology and pharmaceutical development, since 2009. Mr. Adams is a graduate of Austin College in Sherman, Texas with a BA in Business.
- John Dyett
-
John Dyett，自2017年1月起担任我们的董事会成员。Dyett先生自1997年以来一直担任Salem Partners，LLC的联席首席执行官，自2004年以来一直担任Salem Partners Wealth Management，LLC的联席首席执行官。戴伊特帮助亚当斯呼吸治疗公司（Adams Respiratory Therapeutics，Inc.）筹集了多轮风险投资，该公司于2008年被利洁时（Reckitt Benckiser）以23亿美元收购。Dyett先生帮助创立了ZsPharma，Inc.，这是一家专业制药公司。ZsPharma，Inc.于2014年6月成功完成首次公开募股，随后被阿斯利康以27亿美元收购。Dyett先生是Salem Partners Wealth Management的投资委员会成员。Dyett先生还是Gerard Klauer Mattison&Co.，Inc.和Needham and Co.，Inc.的银行家。Dyett先生曾于2016年至2020年担任Sierra Total Return Fund董事会成员。Dyett先生还担任Medley Management和Onconano Medicine的董事会成员。Dyett先生毕业于哈佛大学，获得政府和经济学学士学位。
John Dyett,has served as a member of Femasys Inc. board of directors since January 2017. Mr. Dyett has served as the Co-CEO of Salem Partners, LLC since 1997 and Salem Partners Wealth Management, LLC since 2004. Mr. Dyett helped raise several rounds of venture capital for Adams Respiratory Therapeutics, Inc. which was purchased for $2.3 billion by Reckitt Benckiser in 2008. Mr. Dyett helped launch ZS Pharma, Inc., a specialty pharmaceutical company. ZS Pharma, Inc. completed a successful initial public offering in June 2014 and was subsequently purchased by AstraZeneca for $2.7 billion. Mr. Dyett serves on the investment committee of Salem Partners Wealth Management. Mr. Dyett was also a banker with Gerard Klauer Mattison & Co., Inc. and Needham and Co., Inc. Mr. Dyett previously served on the board of directors of Sierra Total Return Fund from 2016 to 2020. Mr. Dyett also serves on the board of directors of Medley Management and OncoNano Medicine. Mr. Dyett is a graduate of Harvard College with BA in Government and Economics. - John Dyett，自2017年1月起担任我们的董事会成员。Dyett先生自1997年以来一直担任Salem Partners，LLC的联席首席执行官，自2004年以来一直担任Salem Partners Wealth Management，LLC的联席首席执行官。戴伊特帮助亚当斯呼吸治疗公司（Adams Respiratory Therapeutics，Inc.）筹集了多轮风险投资，该公司于2008年被利洁时（Reckitt Benckiser）以23亿美元收购。Dyett先生帮助创立了ZsPharma，Inc.，这是一家专业制药公司。ZsPharma，Inc.于2014年6月成功完成首次公开募股，随后被阿斯利康以27亿美元收购。Dyett先生是Salem Partners Wealth Management的投资委员会成员。Dyett先生还是Gerard Klauer Mattison&Co.，Inc.和Needham and Co.，Inc.的银行家。Dyett先生曾于2016年至2020年担任Sierra Total Return Fund董事会成员。Dyett先生还担任Medley Management和Onconano Medicine的董事会成员。Dyett先生毕业于哈佛大学，获得政府和经济学学士学位。
- John Dyett,has served as a member of Femasys Inc. board of directors since January 2017. Mr. Dyett has served as the Co-CEO of Salem Partners, LLC since 1997 and Salem Partners Wealth Management, LLC since 2004. Mr. Dyett helped raise several rounds of venture capital for Adams Respiratory Therapeutics, Inc. which was purchased for $2.3 billion by Reckitt Benckiser in 2008. Mr. Dyett helped launch ZS Pharma, Inc., a specialty pharmaceutical company. ZS Pharma, Inc. completed a successful initial public offering in June 2014 and was subsequently purchased by AstraZeneca for $2.7 billion. Mr. Dyett serves on the investment committee of Salem Partners Wealth Management. Mr. Dyett was also a banker with Gerard Klauer Mattison & Co., Inc. and Needham and Co., Inc. Mr. Dyett previously served on the board of directors of Sierra Total Return Fund from 2016 to 2020. Mr. Dyett also serves on the board of directors of Medley Management and OncoNano Medicine. Mr. Dyett is a graduate of Harvard College with BA in Government and Economics.
- Charles Larsen
-
Charles Larsen自2015年10月14日起担任董事会成员。Larsen先生在医疗器械行业拥有超过35年的运营和技术经验。他于1992年共同创立Novoste Corporation，并于1999年共同创立The Innovation Factory，通过他在The Innovation Factory的角色，他共同创立了其他公司，包括医疗设备公司，例如AcuFocus，Inc.，Aquesys Inc.，Halscion，Inc.，Neuronetics，Inc.和Sebacia，Inc.。他拥有超过30项已发布的美国和国际医疗设备专利。在加入Novoste之前，Larsen先生曾在Novoste Puerto Rico，Cordis Corporation，Key Pharmaceuticals和Parke-Davis/Warner Lambert担任执行，高级工程和项目管理职务。Larsen先生还担任AcuFocus，CardioFocus，Intuity Medical Inc.和Torax Medical，Inc.的董事会成员，这两家公司均为专业医疗或医疗器械公司。Larsen先生毕业于新泽西州理工学院，获得机械工程学士学位。
Charles Larsen,has served as a member of Femasys Inc. Board since October 2015 and as Chairman of Femasys Inc. Board since 2021.He co-founded Novoste Corporation in 1992 and The Innovation Factory in 1999 and through his role at The Innovation Factory, he co-founded additional companies, including medical device companies such as Acufocus, Inc., AqueSys Inc., Halscion, Inc., Neuronetics, Inc. and Sebacia, Inc. He holds over 30 issued U.S. and international patents on medical devices. Before joining Novoste, Mr. Larsen held positions with Novoste Puerto Rico, Cordis Corporation, Key Pharmaceuticals and Parke-Davis/Warner Lambert in executive, senior engineering and project management roles. Mr. Larsen also serves on the board of directors of Acufocus, CardioFocus, Intuity Medical Inc., and Torax Medical, Inc, each specialty medical or medical device companies. Mr. Larsen is a graduate of the New Jersey Institute of Technology with a B.S. in Mechanical Engineering. - Charles Larsen自2015年10月14日起担任董事会成员。Larsen先生在医疗器械行业拥有超过35年的运营和技术经验。他于1992年共同创立Novoste Corporation，并于1999年共同创立The Innovation Factory，通过他在The Innovation Factory的角色，他共同创立了其他公司，包括医疗设备公司，例如AcuFocus，Inc.，Aquesys Inc.，Halscion，Inc.，Neuronetics，Inc.和Sebacia，Inc.。他拥有超过30项已发布的美国和国际医疗设备专利。在加入Novoste之前，Larsen先生曾在Novoste Puerto Rico，Cordis Corporation，Key Pharmaceuticals和Parke-Davis/Warner Lambert担任执行，高级工程和项目管理职务。Larsen先生还担任AcuFocus，CardioFocus，Intuity Medical Inc.和Torax Medical，Inc.的董事会成员，这两家公司均为专业医疗或医疗器械公司。Larsen先生毕业于新泽西州理工学院，获得机械工程学士学位。
- Charles Larsen,has served as a member of Femasys Inc. Board since October 2015 and as Chairman of Femasys Inc. Board since 2021.He co-founded Novoste Corporation in 1992 and The Innovation Factory in 1999 and through his role at The Innovation Factory, he co-founded additional companies, including medical device companies such as Acufocus, Inc., AqueSys Inc., Halscion, Inc., Neuronetics, Inc. and Sebacia, Inc. He holds over 30 issued U.S. and international patents on medical devices. Before joining Novoste, Mr. Larsen held positions with Novoste Puerto Rico, Cordis Corporation, Key Pharmaceuticals and Parke-Davis/Warner Lambert in executive, senior engineering and project management roles. Mr. Larsen also serves on the board of directors of Acufocus, CardioFocus, Intuity Medical Inc., and Torax Medical, Inc, each specialty medical or medical device companies. Mr. Larsen is a graduate of the New Jersey Institute of Technology with a B.S. in Mechanical Engineering.
- Anne Morrissey
-
Anne Morrissey自2021年5月以来一直担任我们的董事会成员。Morrissey女士于2016年至2020年担任Alydia Health的总裁兼首席执行官，此后担任顾问，直到2021年3月被默克公司收购。她于1998年共同创立了Vivant Medical，在那里她担任业务发展总监直到2000年，并于2011年创立了Ucan Products，在那里她担任首席执行官直到2016年。此前，她还曾担任General Surgical Innovations（随后被Tyco收购）的营销经理。她也曾担任Mentor Worldwide公司（强生公司公司）、Kimberly Clark公司的销售职务。她拥有多项医疗设备专利，并为多家医疗设备公司提供建议，包括Raydiant Oximetry。Morrissey女士毕业于威拉米特大学，获得历史学士学位。
Anne Morrissey,has served as a member of Femasys Inc. board of directors since May 2021. She serves as the President and Chief Executive Officer of May Health (formerly AblaCare), a medical technology company. Ms. Morrissey served as President and Chief Executive Officer of Alydia Health from 2016 to 2020, and thereafter as an advisor until it was acquired by Merck in March 2021. She co-founded Vivant Medical in 1998, where she served as Director of Business Development until 2000, and founded Ucan Products in 2011, where she served as CEO until 2016. Previously, she also served as Marketing Manager at General Surgical Innovations, subsequently acquired by Tyco. She also held positions with Mentor Worldwide, LLC, a Johnson & Johnson Company, and Kimberly Clark in sales roles. She holds several patents on medical devices and advises several medical device companies, including Raydiant Oximetry. Ms. Morrissey is a graduate of Willamette University with a BA in History. - Anne Morrissey自2021年5月以来一直担任我们的董事会成员。Morrissey女士于2016年至2020年担任Alydia Health的总裁兼首席执行官，此后担任顾问，直到2021年3月被默克公司收购。她于1998年共同创立了Vivant Medical，在那里她担任业务发展总监直到2000年，并于2011年创立了Ucan Products，在那里她担任首席执行官直到2016年。此前，她还曾担任General Surgical Innovations（随后被Tyco收购）的营销经理。她也曾担任Mentor Worldwide公司（强生公司公司）、Kimberly Clark公司的销售职务。她拥有多项医疗设备专利，并为多家医疗设备公司提供建议，包括Raydiant Oximetry。Morrissey女士毕业于威拉米特大学，获得历史学士学位。
- Anne Morrissey,has served as a member of Femasys Inc. board of directors since May 2021. She serves as the President and Chief Executive Officer of May Health (formerly AblaCare), a medical technology company. Ms. Morrissey served as President and Chief Executive Officer of Alydia Health from 2016 to 2020, and thereafter as an advisor until it was acquired by Merck in March 2021. She co-founded Vivant Medical in 1998, where she served as Director of Business Development until 2000, and founded Ucan Products in 2011, where she served as CEO until 2016. Previously, she also served as Marketing Manager at General Surgical Innovations, subsequently acquired by Tyco. She also held positions with Mentor Worldwide, LLC, a Johnson & Johnson Company, and Kimberly Clark in sales roles. She holds several patents on medical devices and advises several medical device companies, including Raydiant Oximetry. Ms. Morrissey is a graduate of Willamette University with a BA in History.
- Edward Uzialko
-
Edward Uzialko自2005年8月以来一直担任我们的董事会成员。Uzialko先生从1991年开始担任Lynk Systems，Inc.的创始人兼首席执行官，直到2004年被苏格兰皇家银行收购为止。Lynk提供电子支付，现金分配和电子商务服务。Lynk是一家提供全方位服务的增值经销商，为惠普、摩托罗拉、微软和其他各种技术产品提供硬件、软件和项目开发方面的持续支持。自2007年以来，Uzialko先生还一直担任信用卡处理公司Mainstream Merchant Services的所有者兼首席执行官。Uzialko先生于1969年至1973年在佛罗里达理工学院学习。
Edward Uzialko,has served as a member of Femasys Inc. board of directors since August 2005. Mr. Uzialko was the founder and Chief Executive Officer of Lynk Systems, Inc. from 1991 until it was acquired by Royal Bank of Scotland in 2004. Lynk provided electronic payment, cash dispensing and e-commerce services. Lynk was a full service Value Added Reseller offering ongoing support for hardware, software, and project development for Hewlett Packard, Motorola, Microsoft and various other technological products. Mr. Uzialko has also served as the owner and Chief Executive Officer of Mainstream Merchant Services, a credit card processing firm, since 2007. Mr. Uzialko attended the Florida Institute of Technology from 1969 to 1973. - Edward Uzialko自2005年8月以来一直担任我们的董事会成员。Uzialko先生从1991年开始担任Lynk Systems，Inc.的创始人兼首席执行官，直到2004年被苏格兰皇家银行收购为止。Lynk提供电子支付，现金分配和电子商务服务。Lynk是一家提供全方位服务的增值经销商，为惠普、摩托罗拉、微软和其他各种技术产品提供硬件、软件和项目开发方面的持续支持。自2007年以来，Uzialko先生还一直担任信用卡处理公司Mainstream Merchant Services的所有者兼首席执行官。Uzialko先生于1969年至1973年在佛罗里达理工学院学习。
- Edward Uzialko,has served as a member of Femasys Inc. board of directors since August 2005. Mr. Uzialko was the founder and Chief Executive Officer of Lynk Systems, Inc. from 1991 until it was acquired by Royal Bank of Scotland in 2004. Lynk provided electronic payment, cash dispensing and e-commerce services. Lynk was a full service Value Added Reseller offering ongoing support for hardware, software, and project development for Hewlett Packard, Motorola, Microsoft and various other technological products. Mr. Uzialko has also served as the owner and Chief Executive Officer of Mainstream Merchant Services, a credit card processing firm, since 2007. Mr. Uzialko attended the Florida Institute of Technology from 1969 to 1973.
- Kathy Lee Sepsick
-
自2004年2月以来，我们的创始人Kathy Lee Sepsick一直担任我们的首席执行官兼总裁兼董事会主席。Lee-Sepsick女士在医疗技术行业担任了近三十年的高级管理人员，在成长中的新兴公司和公司运营部门积累了成功的记录。她在全球拥有超过100项Femasys产品和候选产品的专利。Lee-Sepsick女士在初创企业Novoste Corporation（血管内治疗解决方案的开发商）和Salumedica（人工软骨的生物材料开发商）的产品和公司生命周期的各个阶段发挥了重要作用，并承担了国家，运营和执行职责。职业生涯之初，她曾担任Terumo Medical Corporation的产品管理职务，在那里她曾担任波士顿科学国际有限公司的战略合作伙伴的管理职务。Lee-Sepsick女士还担任Georgia Bio的董事会成员。Lee-Sepsick女士毕业于罗格斯大学，拥有MBA和学士学位。在生物化学中。
Kathy Lee Sepsick Femasys Inc. founder, has served as FEMASYS INC President and Chief Executive Officer since 2004 and as FEMASYS INC Chairman from 2004 to 2021. Ms. Lee-Sepsick has served as a senior executive in the medical technologies industry for nearly three decades, compiling a successful track record in growing emerging companies and corporate operating divisions. She holds over 100 patents globally for Femasys products and product candidates. Ms. Lee-Sepsick was instrumental in the various stages of product and company life cycles with strategic, operational, and executive responsibilities, at start-ups Novoste Corporation, developer of intravascular therapy solution and SaluMedica, biomaterial developer of artificial cartilage. At the onset of her career, Ms. Lee-Sepsick served in a product management role at Terumo Medical Corporation, where she was integral in the management of strategic partner, Boston Scientific Corporation. Ms. Lee-Sepsick also serves on the Board of Directors of Georgia Bio. Ms. Lee-Sepsick is a graduate of Rutgers University with an MBA and a BS in Biochemistry. - 自2004年2月以来，我们的创始人Kathy Lee Sepsick一直担任我们的首席执行官兼总裁兼董事会主席。Lee-Sepsick女士在医疗技术行业担任了近三十年的高级管理人员，在成长中的新兴公司和公司运营部门积累了成功的记录。她在全球拥有超过100项Femasys产品和候选产品的专利。Lee-Sepsick女士在初创企业Novoste Corporation（血管内治疗解决方案的开发商）和Salumedica（人工软骨的生物材料开发商）的产品和公司生命周期的各个阶段发挥了重要作用，并承担了国家，运营和执行职责。职业生涯之初，她曾担任Terumo Medical Corporation的产品管理职务，在那里她曾担任波士顿科学国际有限公司的战略合作伙伴的管理职务。Lee-Sepsick女士还担任Georgia Bio的董事会成员。Lee-Sepsick女士毕业于罗格斯大学，拥有MBA和学士学位。在生物化学中。
- Kathy Lee Sepsick Femasys Inc. founder, has served as FEMASYS INC President and Chief Executive Officer since 2004 and as FEMASYS INC Chairman from 2004 to 2021. Ms. Lee-Sepsick has served as a senior executive in the medical technologies industry for nearly three decades, compiling a successful track record in growing emerging companies and corporate operating divisions. She holds over 100 patents globally for Femasys products and product candidates. Ms. Lee-Sepsick was instrumental in the various stages of product and company life cycles with strategic, operational, and executive responsibilities, at start-ups Novoste Corporation, developer of intravascular therapy solution and SaluMedica, biomaterial developer of artificial cartilage. At the onset of her career, Ms. Lee-Sepsick served in a product management role at Terumo Medical Corporation, where she was integral in the management of strategic partner, Boston Scientific Corporation. Ms. Lee-Sepsick also serves on the Board of Directors of Georgia Bio. Ms. Lee-Sepsick is a graduate of Rutgers University with an MBA and a BS in Biochemistry.
- Wendy Perrow
-
Wendy Perrow，自2022年1月起担任Femasys公司董事会成员。她在全球独立咨询公司Princeton Capital Advisors担任高级顾问，并且是马里兰动力基金的顾问委员会成员。此前，她曾于2016年至2020年担任AsclepiX Therapeutics，Inc.的首席执行官和董事会成员。她曾于2008年至2016年担任Alba Therapeutics，Inc.的营销副总裁和首席执行官。此前，她曾担任Sigma-Tau Pharmaceuticals营销与销售副总裁，专注于罕见病和孤儿病产品。她还曾在默沙东公司担任美国和全球营销职位，领导Zocor、Varivax、Cozaar和Hyzaar在美国和全球的发布/计划。佩罗女士的职业生涯始于强生公司的一个部门。Perrow女士还担任马里兰生命科学咨询委员会、马里兰创新倡议的马里兰TEDCO审查委员会和生物领域的妇女成员。佩罗女士毕业于杜克大学、富卡商学院和东伊利诺伊大学，拥有MBA学位和教育学士学位。
Wendy Perrow,has served as a member of Femasys Inc. board of directors since January 2022. She serves as a Senior Advisor at Princeton Capital Advisors, a global independent advisory firm, and she is a member of the board of advisors for the Maryland Momentum Fund. Previously, she served as Chief Executive Officer and Board Member of AsclepiX Therapeutics, Inc. from 2016 to 2020. She was the Vice President of Marketing and then Chief Executive Officer of Alba Therapeutics, Inc. from 2008 to 2016. Previously, she served as Vice President, Marketing & Sales for Sigma-Tau Pharmaceuticals focusing on rare and orphan disease products. She also held positions with Merck & Co. in U.S. and global marketing, where she led U.S. and global launches/initiatives for Zocor, Varivax, Cozaar, and Hyzaar. Ms. Perrow began her career in a division of the Johnson & Johnson Company. Ms. Perrow also serves as member of the Maryland Life Sciences Advisory Board, the Maryland TEDCO review board of the Maryland Innovation Initiative, and Women in Bio. Ms. Perrow is a graduate of Duke University, The Fuqua School of Business with an MBA and Eastern Illinois University with a BS in Education. - Wendy Perrow，自2022年1月起担任Femasys公司董事会成员。她在全球独立咨询公司Princeton Capital Advisors担任高级顾问，并且是马里兰动力基金的顾问委员会成员。此前，她曾于2016年至2020年担任AsclepiX Therapeutics，Inc.的首席执行官和董事会成员。她曾于2008年至2016年担任Alba Therapeutics，Inc.的营销副总裁和首席执行官。此前，她曾担任Sigma-Tau Pharmaceuticals营销与销售副总裁，专注于罕见病和孤儿病产品。她还曾在默沙东公司担任美国和全球营销职位，领导Zocor、Varivax、Cozaar和Hyzaar在美国和全球的发布/计划。佩罗女士的职业生涯始于强生公司的一个部门。Perrow女士还担任马里兰生命科学咨询委员会、马里兰创新倡议的马里兰TEDCO审查委员会和生物领域的妇女成员。佩罗女士毕业于杜克大学、富卡商学院和东伊利诺伊大学，拥有MBA学位和教育学士学位。
- Wendy Perrow,has served as a member of Femasys Inc. board of directors since January 2022. She serves as a Senior Advisor at Princeton Capital Advisors, a global independent advisory firm, and she is a member of the board of advisors for the Maryland Momentum Fund. Previously, she served as Chief Executive Officer and Board Member of AsclepiX Therapeutics, Inc. from 2016 to 2020. She was the Vice President of Marketing and then Chief Executive Officer of Alba Therapeutics, Inc. from 2008 to 2016. Previously, she served as Vice President, Marketing & Sales for Sigma-Tau Pharmaceuticals focusing on rare and orphan disease products. She also held positions with Merck & Co. in U.S. and global marketing, where she led U.S. and global launches/initiatives for Zocor, Varivax, Cozaar, and Hyzaar. Ms. Perrow began her career in a division of the Johnson & Johnson Company. Ms. Perrow also serves as member of the Maryland Life Sciences Advisory Board, the Maryland TEDCO review board of the Maryland Innovation Initiative, and Women in Bio. Ms. Perrow is a graduate of Duke University, The Fuqua School of Business with an MBA and Eastern Illinois University with a BS in Education.
高管简历
中英对照 | 中文 | 英文- Kathy Lee Sepsick
自2004年2月以来，我们的创始人Kathy Lee Sepsick一直担任我们的首席执行官兼总裁兼董事会主席。Lee-Sepsick女士在医疗技术行业担任了近三十年的高级管理人员，在成长中的新兴公司和公司运营部门积累了成功的记录。她在全球拥有超过100项Femasys产品和候选产品的专利。Lee-Sepsick女士在初创企业Novoste Corporation（血管内治疗解决方案的开发商）和Salumedica（人工软骨的生物材料开发商）的产品和公司生命周期的各个阶段发挥了重要作用，并承担了国家，运营和执行职责。职业生涯之初，她曾担任Terumo Medical Corporation的产品管理职务，在那里她曾担任波士顿科学国际有限公司的战略合作伙伴的管理职务。Lee-Sepsick女士还担任Georgia Bio的董事会成员。Lee-Sepsick女士毕业于罗格斯大学，拥有MBA和学士学位。在生物化学中。
Kathy Lee Sepsick Femasys Inc. founder, has served as FEMASYS INC President and Chief Executive Officer since 2004 and as FEMASYS INC Chairman from 2004 to 2021. Ms. Lee-Sepsick has served as a senior executive in the medical technologies industry for nearly three decades, compiling a successful track record in growing emerging companies and corporate operating divisions. She holds over 100 patents globally for Femasys products and product candidates. Ms. Lee-Sepsick was instrumental in the various stages of product and company life cycles with strategic, operational, and executive responsibilities, at start-ups Novoste Corporation, developer of intravascular therapy solution and SaluMedica, biomaterial developer of artificial cartilage. At the onset of her career, Ms. Lee-Sepsick served in a product management role at Terumo Medical Corporation, where she was integral in the management of strategic partner, Boston Scientific Corporation. Ms. Lee-Sepsick also serves on the Board of Directors of Georgia Bio. Ms. Lee-Sepsick is a graduate of Rutgers University with an MBA and a BS in Biochemistry.- 自2004年2月以来，我们的创始人Kathy Lee Sepsick一直担任我们的首席执行官兼总裁兼董事会主席。Lee-Sepsick女士在医疗技术行业担任了近三十年的高级管理人员，在成长中的新兴公司和公司运营部门积累了成功的记录。她在全球拥有超过100项Femasys产品和候选产品的专利。Lee-Sepsick女士在初创企业Novoste Corporation（血管内治疗解决方案的开发商）和Salumedica（人工软骨的生物材料开发商）的产品和公司生命周期的各个阶段发挥了重要作用，并承担了国家，运营和执行职责。职业生涯之初，她曾担任Terumo Medical Corporation的产品管理职务，在那里她曾担任波士顿科学国际有限公司的战略合作伙伴的管理职务。Lee-Sepsick女士还担任Georgia Bio的董事会成员。Lee-Sepsick女士毕业于罗格斯大学，拥有MBA和学士学位。在生物化学中。
- Kathy Lee Sepsick Femasys Inc. founder, has served as FEMASYS INC President and Chief Executive Officer since 2004 and as FEMASYS INC Chairman from 2004 to 2021. Ms. Lee-Sepsick has served as a senior executive in the medical technologies industry for nearly three decades, compiling a successful track record in growing emerging companies and corporate operating divisions. She holds over 100 patents globally for Femasys products and product candidates. Ms. Lee-Sepsick was instrumental in the various stages of product and company life cycles with strategic, operational, and executive responsibilities, at start-ups Novoste Corporation, developer of intravascular therapy solution and SaluMedica, biomaterial developer of artificial cartilage. At the onset of her career, Ms. Lee-Sepsick served in a product management role at Terumo Medical Corporation, where she was integral in the management of strategic partner, Boston Scientific Corporation. Ms. Lee-Sepsick also serves on the Board of Directors of Georgia Bio. Ms. Lee-Sepsick is a graduate of Rutgers University with an MBA and a BS in Biochemistry.
- Daniel Currie
Daniel Currie自2009年起担任运营高级副总裁，此前自2004年起担任运营副总裁。Currie先生在医疗器械行业拥有超过30年的运营经验，包括早期阶段和大型成熟公司的任务。他与研究与开发团队密切合作，实施和管理质量体系，领导CIBA Vision Corporation的合规和投诉处理系统。作为Novoste Corporation的质量主管，他监督并直接参与设计和制造控制，质量审核（包括FDA），评估和管理分包商运营，管理验证系统以及执行产品评估和测试。此外，Currie先生负责评估美国境外能够制造III类医疗设备的设施。选址完成后，柯里先生共同管理了一个团队，以建立完整的制造业务。Currie先生毕业于佐治亚南方大学，获得经济学学士学位。
Daniel Currie,has served as Femasys Inc. Senior Vice President, Operations since 2009 and previously as Femasys Inc. Vice President, Operations since 2004.He worked closely with research and development teams, implemented and managed quality systems, spearheaded compliance and complaint handling systems at CIBA Vision Corporation. As head of Quality at Novoste Corporation, he oversaw and was directly involved in design and manufacturing controls, quality auditing (including FDA), evaluating and managing subcontractor operations, managing validation systems and performing product evaluations and testing. In addition, Mr. Currie was responsible for evaluating facilities outside the United States capable of manufacturing class III medical devices. Once the site was selected, Mr. Currie co-managed a team to establish full manufacturing operations. Mr. Currie is a graduate of Georgia Southern University with a BBA in Economics.- Daniel Currie自2009年起担任运营高级副总裁，此前自2004年起担任运营副总裁。Currie先生在医疗器械行业拥有超过30年的运营经验，包括早期阶段和大型成熟公司的任务。他与研究与开发团队密切合作，实施和管理质量体系，领导CIBA Vision Corporation的合规和投诉处理系统。作为Novoste Corporation的质量主管，他监督并直接参与设计和制造控制，质量审核（包括FDA），评估和管理分包商运营，管理验证系统以及执行产品评估和测试。此外，Currie先生负责评估美国境外能够制造III类医疗设备的设施。选址完成后，柯里先生共同管理了一个团队，以建立完整的制造业务。Currie先生毕业于佐治亚南方大学，获得经济学学士学位。
- Daniel Currie,has served as Femasys Inc. Senior Vice President, Operations since 2009 and previously as Femasys Inc. Vice President, Operations since 2004.He worked closely with research and development teams, implemented and managed quality systems, spearheaded compliance and complaint handling systems at CIBA Vision Corporation. As head of Quality at Novoste Corporation, he oversaw and was directly involved in design and manufacturing controls, quality auditing (including FDA), evaluating and managing subcontractor operations, managing validation systems and performing product evaluations and testing. In addition, Mr. Currie was responsible for evaluating facilities outside the United States capable of manufacturing class III medical devices. Once the site was selected, Mr. Currie co-managed a team to establish full manufacturing operations. Mr. Currie is a graduate of Georgia Southern University with a BBA in Economics.
- Edward Evantash
Edward Evantash，自2021年起担任Femasys Inc.首席医疗官。Evantash博士在医疗事务方面拥有超过20年的领导经验，包括临床研究策略和执行，2009年至2020年3月担任Hologic Inc.医疗总监，2020年3月至2020年8月担任Alydia Health首席医疗官。Evantash博士自2020年8月起担任BEspoke Medical Affairs Solutions的联合创始人和合伙人。Evantash博士开发和管理产品生命周期的发布管道，确定客户知识差距，创建克服商业成功障碍的计划，并制定与医疗保健经济学相一致的战略。在进入行业之前，Evantash博士曾在塔夫茨医疗中心担任普通妇产科主任。此外，他还在塔夫茨大学医学院、东北大学和哈佛医学院担任教职。Evantash博士拥有布兰迪斯大学生物学学士学位和宾夕法尼亚大学医学院医学博士学位。
Edward Evantash,has served as Femasys Inc. Chief Medical Officer since 2021. Dr. Evantash has over 20 years of leadership experience in medical affairs, including clinical study strategy and execution while serving as Medical Director at Hologic Inc. from 2009 to March 2020 and Chief Medical Officer at Alydia Health from March 2020 to August 2020. Dr. Evantash has been Co-Founder and Partner at BEspoke Medical Affairs Solutions since August 2020. Dr. Evantash developed and managed product lifecycle publication pipelines, identified customer knowledge gaps, created programs to overcome barriers to commercial success, and created strategies in alignment with healthcare economics. Before entering industry, Dr. Evantash served as chief of the division of general obstetrics and gynecology at Tufts Medical Center. In addition, he held faculty appointments at Tufts University School of Medicine, Northeastern University and Harvard Medical School. Dr. Evantash holds a BA in biology from Brandeis University and a MD from the University of Pennsylvania School of Medicine.- Edward Evantash，自2021年起担任Femasys Inc.首席医疗官。Evantash博士在医疗事务方面拥有超过20年的领导经验，包括临床研究策略和执行，2009年至2020年3月担任Hologic Inc.医疗总监，2020年3月至2020年8月担任Alydia Health首席医疗官。Evantash博士自2020年8月起担任BEspoke Medical Affairs Solutions的联合创始人和合伙人。Evantash博士开发和管理产品生命周期的发布管道，确定客户知识差距，创建克服商业成功障碍的计划，并制定与医疗保健经济学相一致的战略。在进入行业之前，Evantash博士曾在塔夫茨医疗中心担任普通妇产科主任。此外，他还在塔夫茨大学医学院、东北大学和哈佛医学院担任教职。Evantash博士拥有布兰迪斯大学生物学学士学位和宾夕法尼亚大学医学院医学博士学位。
- Edward Evantash,has served as Femasys Inc. Chief Medical Officer since 2021. Dr. Evantash has over 20 years of leadership experience in medical affairs, including clinical study strategy and execution while serving as Medical Director at Hologic Inc. from 2009 to March 2020 and Chief Medical Officer at Alydia Health from March 2020 to August 2020. Dr. Evantash has been Co-Founder and Partner at BEspoke Medical Affairs Solutions since August 2020. Dr. Evantash developed and managed product lifecycle publication pipelines, identified customer knowledge gaps, created programs to overcome barriers to commercial success, and created strategies in alignment with healthcare economics. Before entering industry, Dr. Evantash served as chief of the division of general obstetrics and gynecology at Tufts Medical Center. In addition, he held faculty appointments at Tufts University School of Medicine, Northeastern University and Harvard Medical School. Dr. Evantash holds a BA in biology from Brandeis University and a MD from the University of Pennsylvania School of Medicine.
- Christine Thomas
Christine Thomas，自2022年10月起担任Femasys Inc.监管和临床事务高级副总裁。Thomas女士在监管和临床事务方面拥有20多年的成功领导经验，包括全球战略制定、运营和医疗设备公司的执行责任，如GE医疗、波士顿科学、Smiths Medical和RTI Surgical，以及为大型临床研究机构艾昆纬提供专注于FDA的顾问专业知识。在她的职业生涯中，托马斯女士曾担任过监管、质量、设计保证、临床和合规方面的副总裁。托马斯女士在多个并购机会中担任过监管、临床和质量方面的主管，这些机会既包括剥离产品线，也包括收购多家公司。托马斯拥有威斯康星大学怀特沃特分校的教育学士学位，目前在约翰霍普金斯大学攻读理学硕士课程。
Christine Thomas,has served as Femasys Inc. Senior Vice President, Regulatory and Clinical Affairs since October 2022. Ms. Thomas has over 20 years of successful leadership in regulatory and clinical affairs, including global strategy development, operations, and executive responsibility for medical device companies, such as GE Healthcare, Boston Scientific, Smiths Medical, and RTI Surgical, as well as providing FDA focused consultant expertise with IQVIA a large clinical research organization. Ms. Thomas has served as vice president of regulatory, quality, design assurance, clinical and compliance over her career. Ms. Thomas has been the regulatory, clinical, and quality lead on multiple M&A opportunities for both divestiture of product lines and acquisitions for several companies. Ms. Thomas holds a BS in Education from University of Wisconsin – Whitewater and is currently in the Johns Hopkins Master of Science program.- Christine Thomas，自2022年10月起担任Femasys Inc.监管和临床事务高级副总裁。Thomas女士在监管和临床事务方面拥有20多年的成功领导经验，包括全球战略制定、运营和医疗设备公司的执行责任，如GE医疗、波士顿科学、Smiths Medical和RTI Surgical，以及为大型临床研究机构艾昆纬提供专注于FDA的顾问专业知识。在她的职业生涯中，托马斯女士曾担任过监管、质量、设计保证、临床和合规方面的副总裁。托马斯女士在多个并购机会中担任过监管、临床和质量方面的主管，这些机会既包括剥离产品线，也包括收购多家公司。托马斯拥有威斯康星大学怀特沃特分校的教育学士学位，目前在约翰霍普金斯大学攻读理学硕士课程。
- Christine Thomas,has served as Femasys Inc. Senior Vice President, Regulatory and Clinical Affairs since October 2022. Ms. Thomas has over 20 years of successful leadership in regulatory and clinical affairs, including global strategy development, operations, and executive responsibility for medical device companies, such as GE Healthcare, Boston Scientific, Smiths Medical, and RTI Surgical, as well as providing FDA focused consultant expertise with IQVIA a large clinical research organization. Ms. Thomas has served as vice president of regulatory, quality, design assurance, clinical and compliance over her career. Ms. Thomas has been the regulatory, clinical, and quality lead on multiple M&A opportunities for both divestiture of product lines and acquisitions for several companies. Ms. Thomas holds a BS in Education from University of Wisconsin – Whitewater and is currently in the Johns Hopkins Master of Science program.
- Dov Elefant
Dov Elefant，2019年9月被任命为Celletar Biosciences，Inc.副总裁兼首席财务官。最近，他于2015年9月至2019年8月担任Akari Therapeutics PLC的首席财务官，这是一家专门治疗自身免疫性和炎症性疾病的上市生物制药公司。在Akari Therapeutics，PLC任职之前，Elefant先生于2012年1月至2015年9月担任Celsus Therapeunics，Inc.（一家公开上市的生物制药公司）的首席财务官。他持有Yeshiva University的会计学士学位。
Dov Elefant was appointed Cellectar Biosciences, Inc. Vice President and Chief Financial Officer in September 2019. Most recently, he served as Chief Financial Officer of Akari Therapeutics PLC, a publicly-traded biopharmaceutical company specializing in treatments for autoimmune and inflammatory diseases, from September 2015 to August 2019. Prior to his service at Akari Therapeutics, PLC, Mr. Elefant served as Chief Financial Officer of Celsus Therapeutics, Inc., a publicly-traded biopharmaceutical company, from January 2012 to September 2015. Mr. Elefant holds a B.S. in accounting from Yeshiva University.- Dov Elefant，2019年9月被任命为Celletar Biosciences，Inc.副总裁兼首席财务官。最近，他于2015年9月至2019年8月担任Akari Therapeutics PLC的首席财务官，这是一家专门治疗自身免疫性和炎症性疾病的上市生物制药公司。在Akari Therapeutics，PLC任职之前，Elefant先生于2012年1月至2015年9月担任Celsus Therapeunics，Inc.（一家公开上市的生物制药公司）的首席财务官。他持有Yeshiva University的会计学士学位。
- Dov Elefant was appointed Cellectar Biosciences, Inc. Vice President and Chief Financial Officer in September 2019. Most recently, he served as Chief Financial Officer of Akari Therapeutics PLC, a publicly-traded biopharmaceutical company specializing in treatments for autoimmune and inflammatory diseases, from September 2015 to August 2019. Prior to his service at Akari Therapeutics, PLC, Mr. Elefant served as Chief Financial Officer of Celsus Therapeutics, Inc., a publicly-traded biopharmaceutical company, from January 2012 to September 2015. Mr. Elefant holds a B.S. in accounting from Yeshiva University.